These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10682136)

  • 1. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.
    Holguín A; Dietrich U; Immelmann A; Soriano V
    Antivir Ther; 1998; 3(3):183-6. PubMed ID: 10682136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
    Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F
    Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
    Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
    J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
    J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.
    Ross L; Johnson M; Ferris RG; Short SA; Boone LR; Melby TE; Lanier R; Shaefer M; St Clair M
    J Hum Virol; 2000; 3(3):144-9. PubMed ID: 10881994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
    J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy and safety of stavudine in pretreated HIV-infected patients.
    Villalba N; Soriano V; Gómez-Cano M; Castilla J; Mas A; González-Lahoz J
    Antivir Ther; 1997 Jul; 2(3):185-9. PubMed ID: 11322273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
    Maxeiner HG; Keulen W; Schuurman R; Bijen M; de Graaf L; van Wijk A; Back N; Kline MW; Boucher CA; Nijhuis M
    J Infect Dis; 2002 Apr; 185(8):1070-6. PubMed ID: 11930317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Resistance of human immunodeficiency virus (HIV) to zidovudine. Genotypic analysis in strains isolated from Chilean patients].
    Vial PA; Vial C; Abarca K; Noriega M; Jiménez G; Labarca J; Gasep J; Palacios O; Pérez C; Acuña G
    Rev Med Chil; 1998 Jan; 126(1):17-26. PubMed ID: 9629750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors.
    Fitzgibbon JE; DiCola B; Arnold E; Das K; Sha BE; Pottage JC; Nahass R; Gaur S; John JF
    Antivir Ther; 2001 Dec; 6(4):231-8. PubMed ID: 11878404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
    Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin MA; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
    Antivir Ther; 2001 Sep; 6(3):179-83. PubMed ID: 11808752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
    J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
    Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H
    Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
    Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
    Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.